Synedgen Receives Supplemental NEI Funding to Identify Lead Development Candidate for Ocular Mustard Gas Injury Program
Retrieved on:
Thursday, October 29, 2020
The additional funding from the NEI provides resources to optimize down-selection to a lead molecule to advance into animal studies.
Key Points:
- The additional funding from the NEI provides resources to optimize down-selection to a lead molecule to advance into animal studies.
- We are thankful for the NEIs continued support of our ocular mustard gas injury program, which has added a number of active novel glycopolymers to our library, said Shenda Baker, Ph.D., President and Chief Executive Officer of Synedgen.
- Synedgens ocular mustard gas injury program supports development of a potential treatment for military and civilian ocular injuries caused by sulfur mustard (SM).
- Using this data, Synedgen plans to select a lead development candidate to progress into animal trials.